Keywords
Affiliated Institutions
Related Publications
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure
Background— Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alon...
A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mo...
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescrib...
The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points
Abstract Background: Cardiac resynchronisation is a promising new intervention for patients with heart failure, left ventricular systolic dysfunction and ventricular dyssynchron...
Publication Info
- Year
- 1993
- Type
- article
- Volume
- 71
- Issue
- 12
- Pages
- 1106-1107
- Citations
- 494
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1016/0002-9149(93)90582-w